Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


No significant difference between LAMAs and LABAs in treating persistent asthma, research finds

Data from 15 randomised trials show that while long-acting muscarinic antagonists reduced exacerbation risk by a third, there was no significant improvement compared with long-acting beta-agonists.

Asthma inhaler, salmeterol, long acting beta agonists (LABA)

Source: Science Photo Library

Study found no significant difference between LABAs and LAMAs in preventing asthma exacerbations 

Long-acting beta-agonists (LABAs), such as salmeterol, are currently the primary add-on therapy for patients with persistent asthma. However, the comparative efficacy of long-acting muscarinic antagonists (LAMAs), such as tiotropium bromide, is less clear.

To explore, researchers carried out a systematic review and meta-analysis of 15 randomised trials comparing a LAMA with placebo or a LABA, as add-on therapy to inhaled corticosteroids (ICS) in 7,122 patients with persistent asthma[1].

The data show that LAMAs reduced the risk of exacerbations requiring systemic corticosteroids by 33% and asthma worsening by 19%, compared with placebo, but there was no significant improvement compared with LABA therapy. The researchers also discovered that triple therapy (ICS+LABA+LAMA) provided no additional benefit over ICS+LABA with regards to exacerbation risk.

Reporting in JAMA (online, 19 March 2018), the researchers said the current evidence does not suggest a significant difference between LABAs and LAMAs in preventing exacerbations but further studies are needed to determine if either is superior.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20204704

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Asthma inhaler, salmeterol, long acting beta agonists (LABA)

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.